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Abstract  
Background: Anxiety and depression symptoms are highly prevalent in people with Chronic 
Obstructive Pulmonary Disease (COPD).  However, there are few large studies of the general 
population that have investigated the association of anxiety and depression with lung function.  
Purpose: To investigate the relationship between anxiety and depression symptoms and lung 
function in a large adult population sample. 
Materials and methods: In this cross-sectional study we included 8,981 men and women 
from the Nord-Trøndelags Health Study, HUNT2 (1995-97), Norway. Symptoms of anxiety 
and depression were self-reported using the Hospital Anxiety and Depression Scale (HADS). 
Lung function was defined by spirometric values and categorized by GOLD – classification.  
Results: Participants with moderate and severe COPD had significant higher crude odds ratio 
for pure depression and mixed symptoms, yet this was mainly explained by differences in age 
and gender between the groups. In gender-stratified analysis women had increased odds for 
symptoms of depression and mixed symptoms due to exacerbated lung function. In contrast, 
men with severe COPD reported higher rates of symptoms of pure anxiety. However, 
statistical evidence was borderline in the fully adjusted models. 
Conclusion: Results from this study indicate a high prevalence of mental distress in severe 
COPD. Gender specific relations between symptoms of anxiety and depression and lung 
function was found; worsened lung function was associated with pure depression and mixed 
symptoms in women, while severe COPD was associated with pure anxiety in men. .These 
patterns might have clinical relevance and should be further investigated.  
Relevance: Untreated depression is known to have unfavorable impact on compliance with 
medical treatment, length of stay in hospitals, number of primary care consultations, symptom 
burden and decreased quality of life among others. Our findings indicate that psychological 
treatment, in particular aiming at depressive symptoms, might have a potential to improve 
quality of life, adherence to treatment and outcome in COPD. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airflow 
limitation that is usually progressive and associated with chronic inflammation in the airways 
(1). The combination of chronic obstructive bronchitis and emphysema are the main factors 
for developing COPD, primarily caused by smoking. Smoking is well known to have a 
negative effect on lung function in general (2).  
Despite the challenge of estimating prevalence of COPD across cultural and research settings, 
the global prevalence is estimated to be approximately 10%, yet it is underlined that this is 
probably an underestimation. COPD is, according to Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), the fourth most common cause of death worldwide (1). 
Earlier COPD were more prevalent among men than women, but increased smoking among 
women in high-income countries has now resulted in more equal prevalence of COPD 
between the genders (3). 
Anxiety and depression are the two of most prevalent mental health conditions in adults, and 
both have a negative impact on health and quality of life in both the general population and 
among people with COPD, though the prevalence of anxiety and depression seems to be 
higher in the COPD population (4, 5).  
Lifetime prevalence of any anxiety and any mood disorder in the general population of 
European countries have been estimated to 13.6% and 12.8%, respectively, whereas the 12 
month prevalence for the same diagnoses were 6.4% and 4.2% (6). The US based 
Epidemiologic Catchment Area program (ECA) reported somewhat higher 12 months 
prevalence; 12.7 % for any anxiety disorder and 5.1 % for any mood disorder in American 
normal population (7).  
Both anxiety and depression have shown great overlap with COPD (5, 8-12), and overall they 
seem to increase with severity of COPD (10). Most studies (8, 13-15) that have found 
associations of COPD with anxiety and depression were carried out in hospital settings or in 
rehabilitation groups, yet evidence from large scale population based studies are lacking. A 
review by Mikkelsen et al (9), states that despite the high prevalence of, and great impact on 
public health, anxiety and depression in COPD are largely ignored, or interpreted as a natural 
development of the pulmonary disease. 
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A review by Hill et al. (8) emphasizes that anxiety and depression represent separate 
constructs, although they often coexist. Result of this review suggests that anxiety and 
depression influence behavior and management of COPD differentially. In those with anxiety, 
smoking and dyspnea are highly associated with COPD. Complex interrelationships between 
dyspnea and anxiety further contribute to the high prevalence of anxiety in COPD (8). 
Smoking assessment and pulmonary rehabilitation, for example supervised exercise training, 
might reduce anxiety. It is known that people with COPD experience loss of function in 
several areas of their lives, and such experiences reinforce the feeling of hopelessness; lack of 
motivation and social withdrawal, which in may lead to depression. In COPD patients, 
psychotherapy combined with physical therapy have improved depression scores (8). A 
clinical study performed by Wilhelm et al (16) conclude that it is a challenge to identify the 
underpinning mechanisms linking respiration and specific clinical symptoms of anxiety, but 
they underline the importance of respiratory physiology for understanding panic disorder.   
A former study of this HUNT 2 cohort examined the associations between objective lung 
function, self-reported symptoms of anxiety and self-perceived dyspnea (17). They found that 
people with anxiety were more likely to report dyspnea than people without anxiety across all 
COPD stages. This suggests that the subjective experience of breathing discomfort, related to 
reduce lung function, can also influence or be influenced by anxiety. Despite the fact that 
anxiety and depression symptoms show great overlap, few previous studies have studied the 
association of symptoms of pure anxiety, pure depression and mixed symptoms with stage of 
COPD. 
The aim of the study is to study self-reported symptoms of anxiety and depression, separately 
and mixed, in association with lung function in 8,981 Norwegian adults who participated in 
the HUNT 2 study. 
Theoretical background 
Chronic Obstructive Pulmonary Disease (COPD) is a collective term for diseases 
characterized by airway resistance, which is not fully reversible. Chronic obstructive 
bronchitis, a state of chronic cough and increased production of sputum, and emphysema, 
caused by reduced elastic rebound effect, represents the majority of the COPD diagnoses (2). 
Early stages of COPD may often be perceived as symptom free, even though a lasting cough 
with sputum is reported. Later symptoms like dyspnea, wheezing, infections, and frequent 
episodes with sputum are common (2, 18). COPD is often diagnosed late. One reason for this 
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can be that people adjust to decreasing lung function and don’t see a doctor and get a 
spirometry examination done before they have severe symptoms (18). COPD is associated 
with poor quality of life (QoL), higher risk of weight loss, muscular atrophy, cardiovascular 
disease, anemia and depression (2, 19, 20).Comorbidity, high mortality and increased length 
of stay (LOS) in hospitals are other outcomes that are associated with chronic obstructive 
pulmonary disease (9).   
COPD is categorized as an epidemic disease (3). In Norway approximately 4% of the 
population has COPD, with an incidence of 0.4% per year (21). In the Nordic countries, it is 
suggested that 7-14% of the adult population have COPD (2). The global prevalence of 
moderate or higher stages of COPD is estimated to be 10.1% by Buist et al. (22). However, 
there are varies in prevalence worldwide depending on smoking habits, indoor air pollution 
and age within the population (23). Also, economic, distance dependent factors and lack of 
medical service in developing countries are possible obstacles for estimating a worldwide 
prevalence of COPD. People having COPD without symptoms are another issue for not being 
able to estimate a global prevalence. Other prevalence variation would be in methods, 
statistical analyzes, population characteristics and diagnostic tools across different cultures 
and research settings and would make comparison between different studies and across 
countries difficult (1, 10). Because of the high prevalence of COPD worldwide, it has been 
increasing focus on different preventable or modifiable risk factors for the disease. Physical 
comorbidity and unfavorable health behavior such including smoking and lifestyle are 
examples of such risk factors.  
According to Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is the 
fourth most common cause of death worldwide (1). About 90% of deaths caused by COPD 
are located in low- and middle-income countries. The gender difference in COPD prevalence 
is decreasing, caused by increased smoking among women in high-income countries (3). 
To diagnose COPD, a lung function test, spirometry, is conducted. Spirometry is a valid test 
for diagnosing COPD (2, 24, 25). The test measures how an individual inhales or exhales 
volumes of air as a function of time, and it is usually carried out at a doctor’s office or at a 
hospital (lung clinic) (24). The test is done by a breathing tube being placed in the patients’ 
mouth. The patient takes a complete maximal inhalation before he is told to blast the air from 
the lungs and continue complete exhalation until the end of test.  A more thorough 
explanation of the spirometry examination in this study is given in the method chapter.  
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The results from the spirometry serve as an objective measurement of respiratory airflow. A 
spirometry test provides many different values reflecting different aspects of lung function. 
To diagnose COPD, forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC) and percent predicted forced expiratory volume in 1 second (pp FEV1) are the most 
commonly used markers. Common criteria for COPD are set by GOLD and are based on a 
FEV1/FVC ratio less than 70% (1, 25). The severity of COPD should be graded by ppFEV1 
and categorized according to the GOLD guidelines. Recently, new Norwegian reference 
equations for lung parameters in the population were established in the Nord-Trøndelag 
Health Study (HUNT 2, 1995-1997) (26). HUNT is a large cohort study of 65,000 adults (27, 
28).  
Anxiety and depression are two of the most prevalent mental health conditions in adults (29). 
Key features of depression are lowered mood, anhedonia, feelings of guilt, poor motivation 
and low self-esteem. In addition, a wide spectrum of physical and functional symptoms, like 
sleep, appetite disturbance and lack of energy, are prominent (8, 30). Main features of anxiety 
are feeling of fear, worrying and worst case scenario-thinking. Somatic symptoms of anxiety 
are nervousness, tremor, sweating, tachycardia, dizziness and tachypnea among others (30). 
In a large cross-sectional study, the European Study of the Epidemiology of Mental Disorders 
(ESEMeD), by Alonso et al. (n=21,425), they found a lifetime prevalence of any anxiety 
disorder to be 13.6% in general population (31). In the same study, lifetime prevalence of any 
mood disorder in the general population was estimated to be 14.0%. The 12-month prevalence 
for any anxiety and any mood disorder was 6.4 % and 4.2%, respectively.    
Diagnosing anxiety and depressive disorders is most often done by a psychiatrist or a clinical 
psychologist. However, in epidemiological studies, due to large sample sizes, the use of 
validated self-report questionnaires is the most common method to assess mental health 
symptoms and behaviors. Many different questionnaires are used for these purposes. 
Hamilton Anxiety Rating Scale (32), Beck Anxiety Inventory (33) and State-Trait Anxiety 
Inventory (34) are examples on questionnaires that exclusively measures anxiety symptoms. 
Questionnaires like Hospital Anxiety and Depression Scale (35), Hopkins Symptom Check 
List (36) and Patient Health Questionnaire (37) cover both anxiety and depression, and 
provide sub scores for anxiety, depression and a total score for mixed anxiety and depression 
symptoms.  
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Symptoms of anxiety and depression have shown great overlap with COPD (5, 8, 11, 12), and 
overall the overlap seem to increase with severity of COPD (10). A review by Mikkelsen et 
al. (9) reveals a significant overrepresentation of anxiety and depression in people with 
COPD, in terms of both self-reported symptoms and psychiatric diagnosis. Factors associated 
with anxiety and depression in COPD are: physical disability, low body mass index, severe 
dyspnea, poor quality of life, female gender, presence of comorbid physical illnesses and 
predicted FEV1 < 50% among others (10). 
Symptoms of anxiety and depression have an additional negative impact on quality of life in 
people with COPD, resulting in increased mortality risk, length of stay in hospital, overall 
symptom burden, greater disability and impaired functional status (5).  
Prevalence of self-reported symptoms of depression in people with COPD, measured by 
HADS-D at a cut off of 8 has been reported to be between 20 and 28 % (38, 39). In contrast to 
this, a study by Engström et al. found a prevalence of 7 %, yet this study had a higher cut off 
value of depression of HADS, at 10 points (12). Further, depression is known to be one of the 
main determinants of impaired quality of life in COPD (12). Importantly, though, the 
depressive syndrome (both self-reported and diagnosed) includes a variety of somatic 
symptoms (40). This brings challenges to separating whether these somatic symptoms are a 
part of the depressive spectrum or rather secondary, caused by somatic illness. The prevalence 
of symptoms of anxiety among people with COPD, measured by HADS, is reported to be 
higher than estimates for depression. Dowson et al. reported that 50 % of COPD inpatients 
had clinically significant anxiety (39) and this is similar to other studies included in a review 
done by Hynninen et al. (4). In another study, the prevalence of symptoms of anxiety was 
found to be 13 % (12).  
Despite the fact that some studies point out the high prevalence of self-reported symptoms of 
anxiety and depression among people with COPD (38, 39), Engström et al. did not find any 
significant differences in anxiety nor depression between people with COPD and those with 
normal lung function (12).  
Both biological and behavioral mechanisms seem to link COPD with increased levels of 
anxiety and depression. Breathing is biologically regulated by neural networks in the 
brainstem, mainly in the Medulla Oblongata (41). Respiration is also controlled by metabolic 
demands and decreased oxygen saturation in the blood, which may cause neuronal damage if 
not compensated (42). Dyspnea, common among people with heart- and lung diseases, is 
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known to be a trigger for anxiety among other conditions, causing a feeling of suffocation (2, 
43). Reversely, the autonomic response of breathing is also constantly responding to changes 
in emotions such as happiness, fear and anxiety (44). Changes in respiration patterns due to 
changes in emotions are regulated by the Amygdala, a part of the reptile brain that has a 
crucial role in processing negative emotions such as fear and anxiety (41, 44). A complex 
interaction between the limbic system (including Amygdala), the cortical structures and 
Medulla Oblongata influences respiration (44).  
Living with a chronic illness like COPD may lead to feelings of frustration, helplessness and 
hopelessness (45), which are common symptoms in anxiety and depression. Also, having 
COPD is associated with poorer global health, reduced physical activity and impaired social 
functioning. All these factors are also well established risk factors for anxiety and depression. 
Hypoxia (caused by COPD and smoking), smoking, exacerbation of COPD and untreated 
chronic depression may all lead to comorbid depression among people with COPD (8, 9).  
Depression is closely linked to smoking (46). Also here, the direction of the association is 
bidirectional (47). Nevertheless it contributes negatively to the COPD - depression linkage.  
Because of the widespread prevalence of symptoms of anxiety and depression it is interesting 
to investigate this in a large population study like HUNT 2. By doing a cross-sectional study 
of these associations, however, we will not be able to say anything of the direction of 
causality. Still, we can estimate the prevalence of anxiety and depression symptoms and 
maybe draw some conclusions towards the need of more adequate treatment of these 
symptoms in people with COPD. 
The importance of looking at associations between COPD and symptoms of anxiety, 
depression and mixed symptoms is among many reasons to find areas where different 
guidelines for treatment are needed. 
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Materials and methods  
Study population and area 
The second wave of the Nord-Trøndelag Health Study (HUNT 2, 1995-97) is a large-scale 
population survey where all resident of Nord-Trøndelag County, aged 20 years and older, 
were invited (28). Nord-Trøndelag County (Figure 1) is in the middle of Norway and is 
sparsely populated with a stable and homogenous population of 127,000 (1995). Nord-
Trøndelag County is very suitable for epidemiological studies, having less than 0.3 % 
migration per year and less than 3 % non-Caucasian. 
   
 
Figure 1 Norway and Nord-Trøndelag County 
 
 
HUNT 2 is a follow-up study of HUNT 1 conducted in 1984-1986.  HUNT 2 had bold focus 
on public health problems like cardiovascular disease, diabetes, obstructive lung disease and 
mental health among others (27). 
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93.898 inhabitants of Nord-Trøndelag County were invited and eligible to participate in 
HUNT 2. The written invitation included a questionnaire 
(http://www.ntnu.no/c/document_library/get_file?uuid=c6786f4d-6175-459c-a80a-
5d4268cc166e&groupId=10304) addressing demographic data, life style, physical and mental 
health factors including the Hospital Anxiety and Depression Scale (HADS) (48). 
The questionnaire was to be filled out prior to the screening and brought to the screening site 
were additional physical examination were conducted. These examinations were 
measurements of blood pressure, heart rate, height, weight, waist and hip circumferences and 
additional clinical measurements in sub-samples like lung function, bone densitometry, 
hearing, vision, headache/migraine, ankle blood pressure and sensibility in the foot (27). 
Compared to other population studies, HUNT 2 has several advantages such as covering a 
total population within a geographical area, wide age range (20 year and older) and a 
relatively high participation rate, 69,5 % (27). 
A study population of a total 65, 233 (69.5 % of invited) attended HUNT 2. Of these a 
respiratory symptom sample (n= 10,148) and a random 5% sample (n=3,322) attended the 
HUNT Lung study (26). This selection was done due to limited capacity for spirometric 
measurements at the screening stations. To be included in the respiratory symptom sample the 
participants must have answered “yes” to any of the following questions: “Do you have or 
have you had asthma?”, “Do you use or have you used asthma medications?” and “Have you 
had attack of wheezing or breathlessness during the last 12 months?” None of the participants 
in the symptom sample were included in the random sample (17).  
Of the 10,148 participant in the symptom sample, 3,537 were excluded due to incomplete 
values of spirometry, possible restrictive lung function or incomplete HADS responds (see 
Figure 2). Of the included people in the random sample, 952 participants were excluded from 
the study by the same criteria, leaving us with a symptom sample of 6,611 and a random 
sample of 2,370. 
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Figure 2 
Float scheme for inclusions criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Invited to HUNT 2 
n= 93,898 (100%) 
Respondents HUNT 2 
n= 65,233 (69.5%) 
Symptom sample 
Spirometry 
n= 6,611 
 5% Random Sample 
n= 3,322 (100%) 
Symptom sample 
n= 10,148 (100%) 
5% random sample 
Spirometry 
n= 2,370 
Excluded 
Incomplete FEV1/FVC, and 
ppFEV1; n= 659 (19.8 %) 
Restrictive lung function; n= 161 
(4.9 %) 
Incomplete HADS; n=132 (4.0%) 
Excluded 
Incomplete FEV1/FVC, and 
ppFEV1; n= 2383 (23.5 %) 
Restrictive lung function; n= 761 
(9.8 %) 
Incomplete HADS; n=393 (3.9  %) 
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Study design 
The study was conducted as a descriptive, cross-sectional study. Cross-sectional study design 
was chosen because it is suitable for studying large populations and is known for its efficiency 
(49, 50). Cross-sectional studies are inexpensive and relatively easy to conduct. The design is 
also fit to measure prevalence of different factors within a population. The method is also 
suitable for identifying associations between disorders. Findings from cross-sectional surveys 
can be generalized to the base population, and to some extent, to other similar populations. On 
the other hand there are limitations using this kind of method, because it can only give clues 
about etiology. Because exposure and outcome are measured simultaneously one can never be 
sure, in the presence of an association, which is the cause and which is the consequence (51).  
Measurements 
Dependent variable – anxiety and depression 
To address symptoms of anxiety and depression in HUNT 2, the Hospital Anxiety and 
Depression Scale (HADS) was included as a part of questionnaire 1 in HUNT 2. The HADS 
is a widely used questionnaire and has been thoroughly validated for use among inpatients in 
both psychiatric and somatic institutions, in primary care settings and in the general 
population (52, 53). It consist of seven items for depression (HADS-D) and seven for anxiety 
(HADS-A).  
Each item has a four-point ordinal scale to describe symptom severity from zero to three (48). 
The score for each subscale ranges from 0-21. 0-7 indicates normal state, 8-10 borderline 
state, and 11-21 anxiety or depression state. If one or two answers were missing, we 
extrapolated the total score by multiplying the sum by 7/5 or 7/6. Anxiety or depression was 
categorized as HADS-A or HADS-D score of 8-21, where 0-7 was no anxiety or no 
depression. Mixed anxiety and depression was defined by cases with both HADS-A and 
HADS-D 8-21.The psychometric properties of the Norwegian version of the HADS have 
found to be excellent in HUNT 2 (53).   
The dependent variables were dichotomized. We took the HADS categorical variable, where 
“0= no anxiety or depression”, “1=pure anxiety”, “2=pure depression”, and “3=mixed anxiety 
and depression “. We then extracted pure anxiety, and dichotomized it into “No anxiety or 
depression = 0”, and “Pure anxiety =1”. The same was done to pure depression and mixed 
symptoms. No anxiety or depression had always the value “0”.  
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Independent variables – Lung function 
Lung function can be measured in several ways (2), but to do a spirometry is common. In 
HUNT 2 lung function was recorded using pneumotachographs (MasterScope spirometer, 
version 4.15, Erich Jaeger GmbH, Wuerzburg, Germany) (26). A pneumotachograph 
measures flow and integrates it into volume which gives us a flow/volume curve.  
To conduct spirometry examinations in HUNT 2, 19 nurses and technicians were organized 
into two teams. Team one covered the 5 most inhabited municipalities and team two covered 
the 18 smaller municipalities (26). The staff was trained to instruct the participants to perform 
three acceptable spirometries, ensuring that the participants produced the highest possible 
peak flows and that expiration continued for six seconds or more. The flow/volume curve 
with the highest values of FEV1 and FVC was retained. The participants were seated and wore 
a nose clip during session. Extension or flexion of the neck was avoided. Further description 
of the spirometry in HUNT 2, is explained elsewhere (26). 
Using spirometry we measured the Forced Expiratory Volume in 1 second (FEV1) and the 
Forced Vital Capacity (FVC). The values of FEV1 and FVC are important indicators for lung 
function, including diagnosing COPD (2).  
Forced Expiratory Volume in 1 second (FEV1) is reproducible. Since the forced expiratory 
volume is independent of effort, this explains a constant value despite repeatedly 
measurements as long the individual maintains the same lung function. Forced Vital Capacity 
(FVC) is not as equally reproducible as FEV1. FVC and FEV1 are dependable of gender, age, 
height and ethnicity (2).  
We included all subjects with baseline spirometry, FEV1, FVC and ppFEV, and who had 
answered the HADS questions from the Lung study and that were present in the symptom or 
random selection in our study (Figure 2).  Local prediction equations for percent predicted 
forced expiratory volume in one second (ppFEV1) were used (26).  
Lung function was defined by forced expiratory volume in one second percentage predicted 
(ppFEV1) and categorized as followed; >100.0, 80.0-99.9, 50.0-79.9, and <50.0.  
COPD was defined according to GOLD classification (1), with a FEV1/FVC ratio <0.70 and 
ppFEV1> 80 (stage 1), ppFEV1 =>50-80, and ppFEV1 <50. Normal lung function was defined 
with FEV1/FVC >0.70 and ppFEV1 >80. Participants with lung function FEV1/FVC <0.70 
and ppFEV1 > 80 was defined as restrictive and excluded from our study population. 
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To obtain statistical power we merged COPD stage 3 (severe COPD) and stage 4 (very severe 
COPD). The COPD- variable was used as a categorical variable in our bivariate and 
multivariate regression analyzes.  
Demographic variables 
Age, gender, cohabitant status, education and work status were used as demographic 
variables. Cohabitant status was dichotomized as living alone (0) or not (1). Education was 
categorized according to the Norwegian education system and was transformed into more (1) 
or less (0) than 9 years of education. Working status was constructed by those who answered 
“yes” to work, self-employed, military service or education (1) and those answering “yes” to 
unemployed, retired, social welfare (0).  
Life style factors 
Smoking, physical activity, and Body Mass Index (BMI) was included as life style factors. 
Smoking was categorizes as current, former and never smoker. Later it was dichotomized as 
non-smoker (0) and current or former smoker (1). Physically activity was dichotomized into 
physically active “yes” (1) or “no” (0). BMI was obtained as a continuous variable. 
Somatic diseases 
Positive answers to “have you or have you ever had…” – heart attack, angina pectoris, 
diabetes, cancer, stroke, or other chronic disease was dichotomized as Chronic somatic 
disease “yes” (1) or “no” (0). 
 
Ethics 
Each participant in HUNT 2 confirmed their participation with a written consent which was 
legit to the screening, subsequent control and follow-up. Each participant also approved for 
their data and blood samples to be used for research (27). They were able to withdraw their 
consent from the study at any time.  
The Norwegian Data Inspectorate, the Regional Committee for Ethics in Medical Research 
and the HUNT publication Review Board approved the protocols for HUNT 2. This study is 
also approved by The Regional Committee for Ethics in Medical Research and The Hunt 
publication Review Board (Appendices 1 and 2). 
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Statistical analyses 
This study aims to investigate the associations between lung function and HADS, with focus 
on COPD and pure depression, pure anxiety and mixed depression and anxiety.  
We used chi-square test and t-test to make a descriptive presentation of our data. This 
presentation of demographic, lifestyle, comorbidity and psychiatry data in the study is shown 
in Table 1.  Further, we performed a bivariate regression, with dichotomized HADS variables 
as dependent variable and lung function as independent variable, to compute crude odds ratios 
(OR) and 95% confidence intervals (CI). A logistic multivariate regression analyze was then 
conducted, with HADS as dichotomized variables and COPD as categorical variables. 
Demographical, life style factors and somatic disease were adjusting variables.  In this 
analysis we estimated adjusted ORs for subtypes of anxiety and depression according to lung 
function and 95% confidence intervals for the same groups. We adjusted for age, sex, physical 
activity, smoking habit, cohabitant and chronic diseases. In a further analysis, we stratified by 
gender. 
Cross tables stratified on gender and age, to make a better overview of our data, are presented 
separately (Appendices 3 and 4).   
P-value <0.05 was defined as statistical significant. The IBM SPSS statistics for Windows 
was our analysis tool (54). We decided not to weigh our sample or to do a trend test for this 
thesis. 
Results 
Table 1 gives a descriptive presentation of the two groups selected for this study; the lung 
symptom group (Symptom group, n= 6,611) and the randomly selected group (Random 
group, n=2,370).The symptom group had a somewhat higher proportion of males (48.3% vs. 
46.3) and mean age was marginally higher (50 vs. 49 years).  Participants in the symptom 
group were more likely to be unemployed, have less education, and more likely to be living 
alone then participants in the random group.  
Concerning life style factors included in this study, more people in the symptom group were 
current smokers, 35.9% vs. 28.9%. More participants in the random group were physically 
active and they had a slightly lower Body Mass Index than the symptom group. 
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In our descriptive presentation (Table 1), The Mean HADS total score of depression was 4.1 
(SD 3.4) for our symptom sample and 3.3 (SD 3.0) for our random sample. Stratifying by 
gender the HADS-Depression score among men was higher than for women; 4.0 (SD 3.3) and 
3.7 (SD 3.3), respectively. This supports the results from our cross tables that men reported 
depression more frequent than women. 
Further, symptoms of pure anxiety, pure depression and mixed anxiety and depression were 
all more commonly reported in the symptom group than in the random group. Also, as 
expected, abnormal lung function measures (spirometry) were more frequent in the symptom 
group then in the random group (moderate COPD: 16.6% vs. 6.9%).  
Because of this considerable overlap between the two study groups in terms of reduced lung 
function, we chose to merge the two groups and then divide into conventional classification of 
lung function (GOLD-classification) for the further analyses.  
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Table 1 
Descriptive presentation of symptom group and random group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Dichotomized answer “yes” to have you ever had or do you have Heart attack, Angina Pectoris, Diabetes, Cancer, Stroke 
and other chronic somatic disorder 
b) A score > 8 for symptoms of anxiety and/or depression in HADS was dichotomized into “No anxiety or depression”, 
“Pure anxiety”, “Pure depression” or “Mixed anxiety and depression” 
c) ppFEV1 percent predicted forced expiratory volume in one second 
d) According to GOLD-classifications (see method) 
  
 Symptom 
(% or SD) 
Random 
(% or SD) 
 
p-value 
Participants (symptom/random)    
Demographic 
Male sex (6611/2370) 
Age (6611/2370) 
Cohabitant (5036/1851) 
Employed (6521/2340) 
Education (6380/2295) 
- <= 9 years 
- > 9 years 
 
Lifestyle 
Body Mass Index (6972/2470) 
Smoking (6522/2333) 
- Never smoker 
- Former smoker 
- Current smoker 
 
Physical activity (5050/1850) 
- Inactive 
- Moderate 
- Physical active 
 
Somatic disordersa) 
             One or more chronic disease 
 
Hospital Anxiety and Depression Scale 
HADS categoriesb) (6611/2370) 
- No anxiety or depression 
- Pure anxiety 
- Pure depression 
- Mixed anxiety and depression 
Mean HADS sum total score 
- Anxiety (6445/2248) 
- Depression (7197/2476) 
 
Lung function 
ppFEV1c) (6611/2370) 
- =>100.0 
- 80.0 – 99.9 
- 50.0 – 79.9 
- <50.0 
COPDd) severity (6611/2370) 
- No COPD 
- Mild 
- Moderate 
- Severe 
 
3196 (48.3) 
49.8 (16.7) 
4273 (84.8) 
4108 (63.0) 
 
2472 (38.7) 
3908 (61.3) 
 
 
26.9 (4.4) 
 
2250 (34.5) 
1928 (29.6) 
2344 (35.9) 
 
 
2353 (46.6) 
2450 (48.5) 
247 (4.9) 
 
 
1628 (24.6) 
 
 
 
4354 (65.9) 
1215 (18.4) 
349 (5.3) 
693 (10.5) 
 
6.0 (3.7) 
4.1 (3.4) 
 
 
 
1930 (29.2) 
3219 (48.7) 
1095 (16.6) 
367 (5.6) 
 
4719 (71.4) 
430 (6.5) 
1095 (16.6) 
367 (5.6) 
 
1097 (46.3) 
48.9 (15.9) 
1623 (87.7) 
1669 (71.3) 
 
776 (33.8) 
1519 (66.2) 
 
 
26.2 (3.8) 
 
1011 (43.3) 
647 (27.7) 
675 (28.9) 
 
 
762 (41.2) 
988 (53.4) 
100 (5.4) 
 
 
398 (16.8) 
 
 
 
1824 (77.0) 
305 (12.9) 
82 (3.5) 
159 (6.7) 
 
5.1 (3.2) 
3.3 (3.0) 
 
 
 
1030 (43.5) 
1153 (48.6) 
163 (6.9) 
24 (1.0) 
 
2058 (86.8) 
125 (5.3) 
163 (6.9) 
24 (1.0) 
 
 
0.085 
0.031 
0.003 
<0.001 
 
<0.001 
<0.001 
 
 
<0.001 
<0.001 
 
 
 
 
<0.001 
 
 
 
 
 
<0.001 
 
 
<0.001 
 
 
 
 
 
<0.001 
<0.001 
 
 
<0.001 
 
 
 
 
0.001 
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Table 2 presents crude and adjusted odds ratios (OR) for symptoms of pure anxiety, pure 
depression and mixed anxiety and depression above cut-off levels, in association with lung 
function.  Lung function is defined according to GOLD classification (see Methods); here 
after referred to as mild COPD, moderate COPD or severe COPD. Those with normal lung 
function represented the reference group in this study.  
Crude associations of symptoms of pure anxiety weakened with decreasing lung function, yet 
this was explained by differences in age and gender distribution. Further adjustment did not 
alter these results.  
In the crude analysis there was a 3-fold increased odd for pure depression in the group for 
severe COPD, but this effect was attenuated with further adjustment, and towards the null in 
Model 3. In the fully adjusted model, the following covariates influenced the association 
between COPD and pure depression the most; male gender (OR 1.98 and 95% CI 1.44-2.70), 
age (OR 1.04 and 95% CI 1.03-1.06) and education > 9 yrs. (OR 1.35 and 95% CI 0.99-1.83). 
In contrast, living in a relationship (OR (CI): 0.51 (0.35-0.76) and physical activity (OR 0.57 
and 95% CI (0.42-0.75), were protective factors in the association between COPD and pure 
depression.  
In contrast to symptoms of anxiety, there was a tendency of increasing ORs for depression 
with decreasing lung function. Of note, no statistical test was run to test this trend in the 
current study. 
The pattern was similar for symptoms of mixed anxiety and depression, yet the ORs were 
smaller and less robust for adjustment; unadjusted excess risk in the COPD 3 group was 50% 
higher than in the reference group, but was non-existing in Model 2.  
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Table 2 
Crude and adjusted ORs for pure anxiety, pure depression and mixed anxiety and depression symptoms
a) 
in association with lung function 
 
Exposure 
 
Pure anxiety 
OR (CI) 
 
p-value 
 
Pure depression 
OR (CI) 
 
p-value 
Mixed anxiety and 
depression 
OR (CI 
 
p-value 
Lung function 
- Mild COPD 
- Moderate COPD 
- Severe COPD 
Model 1
b)
  
Lung function 
- Mild COPD 
- Moderate COPD 
- Severe COPD 
Model 2
c)
  
Lung function 
- Mild COPD 
- Moderate COPD 
- Severe COPD 
Model 3
d)
  
Lung function 
- Mild COPD 
- Moderate COPD 
- Severe COPD 
 
0.88 (0.69-1.12) 
0.90 (0.76-1.07) 
0.70 (0.51-0.97) 
 
 
1.04 (0.81-1.33) 
1.12 (0.94-1.34) 
0.97 (0.69-1.35) 
 
 
0.98 (0.736-1.31) 
1.07 (0.866-1.33) 
0.74 (0.504-1.19) 
 
 
1.09 (0.78-1.46) 
1.15 (0.88-1.45) 
1.17 (0.67-1.81) 
 
0.289 
0.217 
0.034 
 
 
0.763 
0.219 
0.852 
 
 
0.896 
0.515 
0.241 
 
 
0.679 
0.332 
0.694 
 
1.55 (1.06-2.26) 
1.91 (1.49-2.46) 
3.28 (2.34-4.60) 
 
 
0.98 (0.66-1.44) 
1.02 (0.78-1.33) 
1.40 (0.98-2.02) 
 
 
0.77 (0.47-1.29) 
1.06 (0.76-1.48) 
1.28 (0.80-2.03) 
 
 
0.86 (0.49-1.49) 
0.95 (0.63-1.42) 
1.01 (0.51-1.89) 
 
0.022 
<0.001 
<0.001 
 
 
0.906 
0.910 
0.065 
 
 
0.326 
0.752 
0.301 
 
 
0.580 
0.796 
0.968 
 
1.15 (0.86-1.54) 
1.34 (1.10-1.63) 
1.52 (1.11-2.09) 
 
 
1.06 (0.79-1.43) 
1.17 (0.95-1.44) 
1.26 (0.90-1.75) 
 
 
0.996 (0.69-1.43) 
1.01 (0.77-1.32) 
0.76 (0.47-1.23) 
 
 
0.90 (0.58-1.39) 
0.80 (0.57-1.12) 
0.66 (0.34-1.28) 
 
0.361 
0.004 
0.009 
 
 
0.706 
0.144 
0.176 
 
 
0.983 
0.963 
0.264 
 
 
0.895 
0.798 
0.657 
       
a) Cut off for pure anxiety, pure depression and mixed anxiety and depression was > 8 
b) Adjusted for gender and age 
c) Adjusted for cohabitant, work status and education 
d) Adjusted for physical activity, body mass index (BMI), somatic diseases (Heart attack, Angina Pectoris, Diabetes, Cancer, Stroke and other chronic somatic disorder) and 
smoking
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Given the results for pure depression, we next performed the same logistic regression analysis 
stratified by gender (Table 3). In male participants, the crude OR for symptoms of pure 
anxiety decreased as lung function deteriorated. After adjusting for age, this pattern changed, 
and in Model 3 men with severe COPD had almost 60 % higher OR for symptoms of pure 
anxiety than those with normal lung function. Still, statistical evidence for this finding is at 
borderline. Females had a slight increase in OR of pure anxiety from mild COPD to moderate 
COPD, and then a decrease from moderate COPD to severe COPD. The tendency remained 
the same for Model 1, Model 2 and Model 3 for females.  
In males, unadjusted logistic regression showed an increase in OR for pure depression with 
decreasing lung function.  This effect was attenuated beyond statistical significance in the 
further steps of adjustment. For women, there was a significant increase in crude OR for 
symptoms of pure depression for all three stages of COPD. In Model 1, the OR for women 
with severe COPD was reduced by 50%. A two-fold increased OR for pure depression 
remained robust to further adjustments in females. Although statistic evidence is weak, the 
point estimates (ORs) indicate that the association with depression is stronger in females than 
males.  
In the crude logistic regression on symptoms of mixed anxiety and depression, men had an 
increased OR in mild and moderate COPD, and decrease in OR for moderate to severe 
COPD. This pattern remained throughout the fully adjusted model, and ORs generally 
decreased with adjustment. In Model 3 men with moderate COPD had a reduced OR (0.61 
and 95% CI 0.37-1.00). Women with moderate, OR (1.59 and 95% CI 1.20-2.09) and severe, 
OR (2.35 and 95% CI 1.51-3.65) COPD had a significant increase of mixed symptoms in the 
crude analysis. After adjustment for age there was still an increase in line with exacerbated 
lung function, but only statistically significant for those with severe COPD, OR (1.75 and 
95% CI 1.12-2.76).  
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Table 3 
Crude and adjusted ORs for pure anxiety, pure depression and mixed anxiety and depression 
symptoms
a) 
in association with lung function, stratified by gender 
 
 
 
Exposure 
 
Pure 
 Anxiety 
OR (CI) 
 
 
p-
value 
 
Pure 
Depression 
OR (CI) 
 
 
p- 
value 
Mixed 
anxiety and 
depression 
OR (CI) 
 
 
P-
value 
Lung function 
Female 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
 
Male 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
Model 1b 
Lung function 
Female 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
 
Male 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
Model 2c 
Lung function 
Female 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
 
Male 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
Model 3d 
Lung function 
Female 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
 
Male 
COPD 1 (mild) 
COPD 2 (moderate) 
COPD 3 (severe) 
 
 
 
0.98 (0.69-1.39) 
1.09 (0.87-1.37) 
0.81 (0.50-1.32) 
 
 
0.88 (0.62-1.25) 
0.82 (0.63-1.05) 
0.73 (0.47-1.13) 
 
 
 
1.01 (0.72-1.44) 
1.15 (0.90-1.45) 
0.87 (0.53-1.41) 
 
 
1.12 (0.76-1.07) 
1.18 (0.90-1.55) 
1.27 (0.80-2.02) 
 
 
 
0.96 (0.63-1.44) 
0.99 (0.73-1.32) 
0.61 (031-1.19) 
 
 
1.06 (0.70-1.59) 
1.29 (094-1.77) 
1.14 (0.64-2.01) 
 
 
 
0.99 (0.63-1.59) 
1.11 (0.79-1.58) 
0.93 (0.45-2.40) 
 
 
1.19 (0.78-1.07) 
1.27 (0.88-1.83) 
1.57 (0.84-2.96) 
 
 
0.913 
0.462 
0.396 
 
 
0.485 
0.116 
0.156 
 
 
 
0.941 
0.268 
0.561 
 
 
0.537 
0.243 
0.318 
 
 
 
0.824 
0.917 
0.149 
 
 
0.917 
0.121 
0.662 
 
 
 
0.988 
0.545 
0.930 
 
 
0.423 
0.195 
0.160 
 
 
2.07 (1.14-3.77) 
2.00 (1.30-3.08) 
3.59 (1.94-6.64) 
 
 
1.20 (0.74-1.95) 
1.69 (1.24-2.30) 
2.78 (1.85-4.18) 
 
 
 
1.34 (0.72-2.48) 
1.15 (0.73-1.80) 
1.78 (0.94-3.35) 
 
 
0.82 (0.50-1.35) 
0.97 (0.69-1.35) 
1.30 (0.84-2.02) 
 
 
 
0.71 (0.45-2.01) 
1.13 (0.63-2.04) 
1.90 (0.64-1.94) 
 
 
0.79 (0.44-1.41) 
1.03 (0.68-1.54) 
1.12 (0.64-1.94) 
 
 
 
0.91 (0.31-2.67) 
0.88 (0.39-2.00) 
2.46 (0.74-8.13) 
 
 
0.84 (0.44-1.61) 
0.99 (0.62-1.58) 
0.82 (0.38-1.76) 
 
 
0.017 
0.002 
<0.001 
 
 
0.463 
0.001 
<0.001 
 
 
 
0.356 
0.556 
0.076 
 
 
0.433 
0.838 
0.238 
 
 
 
0.516 
0.684 
0.128 
 
 
0.423 
0.904 
0.696 
 
 
 
0.858 
0.760 
0.141 
 
 
0.605 
0.963 
0.604 
 
 
 
1.31 (0.86-2.00) 
1.59 (1.20-2.09) 
2.35 (1.51-3.65) 
 
 
1.08 (0.72-1.62) 
1.20 (0.90-1.59) 
1.10 (0.68-1.79) 
 
 
 
1.11 (0.72-1.71) 
1.28 (0.96-1.71) 
1.76 (1.12-2.76) 
 
 
1.02 (0.67-1.54) 
1.10 (0.81-1.50) 
0.98 (0.59-1.61) 
 
 
 
1.16 (0.69-1.98) 
1.13 (0.78-1.63) 
1.37 (0.69-1.98) 
 
 
0.87 (0.53-1.44) 
0.93 (0.64-1.37) 
0.43 (0.19-0.96) 
 
 
 
1.13 (0.61-2.13) 
1.07 (0.67-1.72) 
1.87 (0.76-4.65) 
 
 
0.77 (0.41-1.45) 
0.61 (0.37-1.00) 
0.38 (0.13-1.10) 
 
 
0.215 
0.001 
<0.001 
 
 
0.723 
0.209 
0.704 
 
 
 
0.642 
0.092 
0.015 
 
 
0.925 
0.525 
0.923 
 
 
 
0.573 
0.534 
0.324 
 
 
0.588 
0.717 
0.038 
 
 
 
0.691 
0.767 
0.176 
 
 
0.363 
0.052 
0.074 
a) Cut off for pure anxiety, pure depression and mixed anxiety and depression was > 8 
b) Adjusted for age 
c) Adjusted for a + cohabitant, education and work status 
d) Adjusted for a+ b+BMI, physical activity, smoking and somatic diseases (Heart attack, Angina Pectoris, Diabetes, 
Cancer, Stroke and other chronic somatic disorder)
20 
 
Appendices 3a and b present cross tables for HADS categories by COPD class, stratified by 
gender and age under or above 50 years, to help give a more detailed overview of the 
distribution of subtypes of anxiety and depression depending on lung function in the study 
sample. Of note, low numbers of COPD cases under the age of 50 years make firm   
Discussion 
This population based study indicates gender specific associations of symptoms of anxiety 
and depression with lung function.  The prevalence of depression was higher in males than 
females in our total sample, but only women had increased odds for depression and mixed 
anxiety and depression attributed to decreased lung function. Inversely, our results indicate 
that only men report higher rates of pure anxiety in severe COPD. Statistical evidence was, 
however, borderline.  Findings regarding depression in COPD are in keeping with literature, 
yet the observed increased risk for anxiety in males with severe COPD contradicts earlier 
findings (4, 8, 14, 55). 
Gender differences in anxiety and depression in the general population 
In general, depression is thought to be more common among women (13). There might be 
different reasons for this; women might actually be more vulnerable to depression, but they 
are also more likely to admit and acknowledge depressive symptoms and seek help than men 
(56).  In contrast, however, women reported depression less frequent than men. This may be 
caused by the properties of HADS and the sampling procedures in this study. This scale 
focuses mainly on anhedonia in depression, which has proven to be a gender neutral 
depressive symptom (57).Of note; Stordal et al. (58) found no differences between the 
genders in their study of the total HUNT 2 population. Further, one of the purposes for the 
HADS scale is to exclude the somatic symptoms of anxiety and depression among physically 
ill people. It is known that women more often report somatic symptoms of depression than 
men, and in sum these factors may explain the observed gender patterns described above.  
Some studies report that depression increase with age, yet findings are still conflicting (59, 
60). Stordal et al. (59), found a close to linear increase in depression symptoms with age in 
both genders. In a further study, the same authors found that somatic symptoms and diagnoses 
explained most of the association between depression and age (61). These studies were 
conducted in the same population as the present study. In our study depression symptoms 
increased with 4% per year of age. This close relationship was illustrated by the marked drop 
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in OR after age adjustment in our logistic regression analysis (Table 2). Of note, the close 
association of HADS-Depression score with age have been observed in previous population 
based studies using the HADS scale, and might be explained by anhedonia, which is one of 
main symptoms of depression and tend to increase with age (59, 62).  
Gender specific associations between symptoms of anxiety and depression and COPD 
The findings for symptoms of depression in our study are consistent with a review by Hill et 
al. (8), where they found that more severe COPD usually correlates with higher depression 
score on screening instruments. A gender specific finding, showing that women had higher 
odds for depression with decreasing lung function is also documented in earlier studies (13, 
14, 55). As observed in most previous studies of patient samples and in the general 
population, women with COPD seemed to be more exposed to depression symptoms than 
men with the same condition in our study. In a study by Di Marco et al (14), females had 
higher levels of anxiety and depression, and also reported higher level of dyspnea which 
correlated with depression. Dyspnea is thought to be associated with anxiety, and within the 
lung symptom sample in HUNT Leivseth et al. (17) reported that people with anxiety 
symptoms reported more dyspnea than people without anxiety.  Overall, studies report that 
depression in association with COPD has a larger impact on women than men in regards to 
quality of life and feeling of dyspnea (55, 63). 
Another explanation for elevated depression scores in poor lung function might be the fact 
that people with severe COPD often use large doses of steroids for short periods of time, or 
low doses for long periods of time, both well-known risk factors for depression (64). 
However, to our best knowledge no studies have examined gender differences in depression 
caused by steroid treatment in COPD. We had no data on use of medications in our study and 
we were therefore not able to investigate these issues further.   
Symptoms of comorbid depression in patients with COPD are associated with poorer survival, 
longer hospitalization, persistent smoking, increased symptom burden and poorer physical 
and social function. Interventions that reduce depressive symptoms may potentially affect 
COPD outcomes (11). According to Hynninen et al. (63), cognitive behavioral therapy (CBT) 
improves symptoms of anxiety and depression in patients of both genders with COPD. Of 
note, women had higher symptom levels of anxiety and depression than men throughout their 
study. In the present study, associations of symptoms of pure anxiety weakened with 
exacerbating lung function. This was explained by gender and age in our logistic regression 
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analyses (Table 2). These findings are in accordance to Engström et al. (12), who found a 
somewhat higher percentage of anxiety among patients with COPD, but it was not statistically 
significant.  
The earlier mentioned review by Hynninen et al. (4) includes 19 studies of anxiety in COPD 
patients. Four of these studies used HADS, and found a prevalence of anxiety between 13%- 
57%. These numbers are similar to the prevalence of symptoms of pure anxiety in our study. 
It is difficult to compare our results directly to these findings since none of the studies 
included in the report by Hynninen et al. had more than 141 participants, and more than 50% 
of the participant had to be diagnosed with COPD.  Our study has a far larger sample and 
there are reasons to believe that we also investigated participants in a stable period of their 
COPD, and our selection was not based on a COPD diagnose.  
Laurin et al. (55), who investigated psychiatric disorder among COPD outpatients in a stable 
phase found a higher rate of anxiety than depression in their study. They also found that 
women had 1.5 times the rate of anxiety disorder than men. This was opposite our findings, 
where no associations of anxiety with COPD severity throughout our regression analyses.   
Some of the differences in results between our study and other studies might be the explained 
by the different instruments used to address symptoms of anxiety and depression. Some 
instruments exclusively measure anxiety symptoms (32-34) and others provide a sub score for 
anxiety-related symptoms, which makes it possible to investigate self-reported symptoms of 
pure anxiety (35-37). Anxiety and depressive symptom overlap greatly (53). In order to avoid 
misclassification between anxiety and depression, we chose to study symptoms of pure 
anxiety and depression as mutually exclusive symptom groups. Most previous studies using 
HADS and other instruments have not done this, and therefore most of them have included 
many participants with anxiety in their “depression group”, and vice versa.  
Overall, people with severe COPD, had a 52% increased odds of   reporting mixed anxiety 
and depression symptoms, compared to those with normal lung function. Women with severe 
COPD had 2-fold increased odds for reporting mixed symptoms compared to men.  We have 
not been able to find studies who investigate self-reported symptoms of mixed anxiety and 
depression within lung function.  However, Katon et al. (65) emphasizes the importance of 
revealing subclinical mixed anxiety and depression in the population, because they tend to 
have many medical non-explained symptoms and are at risk of more severe affective and 
anxiety disorders when exposed to stress, i.e. physical sickness. Laurin et al (55), found a 
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prevalence of both current anxiety and mood disorder of 14% (n=16), but did not discuss 
these findings in relation to single conditions further. However, findings from their study are 
similar to the prevalence of symptoms of mixed anxiety and depression in the present study, 
ranging 6.6-16.5% for men and 7.7-19.2% for women. Das-Munshi et al. (66) found a 
prevalence of 8.8 % in the general population of mixed anxiety-depressive disorder (MADD), 
a subclinical category that do not meet the diagnostic criteria of clinical anxiety, depression or 
comorbid depression and anxiety disorders according to ICD-10. MADD may account for 
half of all cases of common mental disorder in Great Britain, and have similar impact on 
quality of life as anxiety and depression. It also has a negative impact upon population health 
and well-being. These finding strengthen the importance of revealing mixed anxiety and 
depression in the population. 
Strengths and limitations 
The current study has several strengths. The sample size is large and includes female and 
male participants across the whole adult lifespan. Lung function was clinically examined 
using spirometry as recommended by international guidelines. Further, a wide range of 
baseline variables known to influence both mental health and lung function for all participants 
was included in the study. Our data was collected using validated and well established 
methods for assessment of lung function and anxiety and depression. The study design is fit 
for investigation in large populations and for identifying associations between disorders. 
Findings from such study may be generalized to the base population and, to some extent, to 
similar population. The HADS is a reliable questionnaire because of its function of isolating 
psychiatric symptoms from physical symptoms (48). As far as we know, the symptoms of 
pure anxiety and pure depression have not earlier been similar defined in large population 
studies. Some limitations must be acknowledged. In HUNT 2, post-bronchodilator spirometry 
was conducted only for those with indication of bronchial obstruction (FEV1/FVC<0.75) in 
pre-bronchodilator spirometry. This may probably cause some misclassification according to 
the COPD diagnosis and must be interpreted as a limitation. Since we used self-reported 
symptoms of anxiety and depression instead of clinical psychiatric diagnoses, a direct 
comparison with results from many of the previous studies cannot be done. However this 
method is common in clinical practice and in epidemiological studies.  
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Conclusion 
Results from this study indicate a high prevalence of mental distress in severe COPD, and 
gender specific relationships between symptoms of anxiety and depression, and lung function; 
in women depression was strongly associated with exacerbated lung function, while only men 
reported symptoms of anxiety associated with worsened lung function. There should be a 
greater focus on early detection and treatment of psychological symptoms among people with 
COPD. The assessment can be done by self-reported questionnaires, like the HADS, as a part 
of COPD treatment. This is one of the first studies, in a large general population, that 
investigate anxiety and depression sub types. Findings must therefore be replicated before 
new, possible gender specific strategies can be developed and implemented.  
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Appendices 
 
Appendix 1 
Cross table for women for HADS with COPD, stratified by age group <50 years> 
 
Appendix 2 
Cross table for men for HADS with COPD, stratified by age group <50 years> 
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Appendix 3 
Cross table for women for HADS with COPD, stratified by age group <50 years> 
a) Adjusted for gender and continuous age 
b) Adjusted for cohabitant, work status and education 
c) Adjusted for physical activity, body mass index (BMI), somatic diseases (Heart attack, Angina Pectoris, Diabetes, Cancer, Apoplexy and other chronic somatic disorder) and 
smoking. 
 
 
 
 
 
 
 
 
 
 
 
 
< 50 years 
  
 
  
 
  
> 50 years 
    
  No 
Anxiety or 
depression 
 
Pure 
anxiety 
 
Pure 
depression 
Mixed 
Anxiety 
and 
depression 
 
 
Total 
 No 
Anxiety and 
depression 
 
Pure 
anxiety 
 
Pure 
depression 
Mixed 
Anxiety and 
depression 
 
 
Total 
Normal lung function 1600 
69.1 % 
498 
21.5 % 
39 
1.7 % 
178 
7.7 % 
2315 
100 % 
 941 
64.9 % 
267 
18.4 % 
68 
4.7 % 
174 
12.0 % 
1450 
100 % 
COPD 1 (mild)
a 
61 
63.5 % 
23 
24.0 % 
3 
3.1 % 
9 
9.4 % 
96 
100 % 
 88 
64.2 % 
21 
15.3 % 
10 
7.3 % 
18 
13.1 % 
137 
100 % 
COPD 2 (moderate)
b 
88 
63.3 % 
27 
19.4 % 
5 
3.6 % 
19 
13.4 % 
139 
100 % 
 244 
60.5 % 
82 
20.3 % 
23 
5.7 % 
54 
13.4 % 
403 
100 % 
COPD 3 (severe)
c 
12 
52.2 % 
6 
26.1 % 
1 
4.3 % 
4 
17.4 % 
23 
100 % 
 74 
59.2 % 
15 
12.0 % 
12 
9.6 % 
24 
19.2 % 
125 
100 % 
Total 1761 
68.4 
554 
21.5 % 
48 
1.9 % 
210 
8.2 % 
2573 
100 % 
 1347 
63.7 % 
385 
18.2 % 
113 
5.3 % 
270 
12.8 % 
2115 
100  
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Appendix 4 
Cross table for men for HADS with COPD, stratified by age group <50 years> 
 < 50 years 
 
     > 50 years 
 
    
  No 
Anxiety 
and 
depression 
 
Pure 
anxiety 
 
Pure 
depression 
Mixed 
Anxiety 
and 
depression 
 
 
Total 
 No 
Anxiety 
and 
depression 
 
Pure 
anxiety 
 
Pure 
depression 
Mixed 
Anxiety 
and 
depression 
 
 
Total 
Normal lung function 1356 
71.9% 
324 
19.3 % 
57 
3.0 % 
150 
7.9 % 
1887 
100 % 
 814 
72.4 % 
110 
9.8 % 
99 
8.8 % 
102 
9.1 % 
1125 
100 % 
COPD 1 (mild)
a 
80 
75.5 % 
18 
17.0 % 
1 
0.9 % 
7 
6.6 % 
106 
100 % 
 152 
70.4 % 
23 
10.6 % 
19 
8.8 % 
22 
10.2 % 
216 
100 % 
COPD 2 (moderate)b 109 
71.2 % 
25 
16.3 % 
3 
2.0 % 
16 
10.5 % 
153 
100 % 
 394 
70.0 % 
57 
10.1 % 
58 
10.3 % 
54 
9.6 % 
563 
100 % 
COPD 3 (severe)c 8 
44.4 % 
7  
38.9 % 
0 
0.0 % 
3 
16.7 % 
18 
100 % 
 157 
71.3 % 
17 
7.6 % 
33 
14.7 % 
18 
8.0 % 
225 
100 % 
Total 1553 
71.8 
374 
17.3 % 
61 
2.8 % 
176 
8.1 % 
2164 
100 % 
 1517 
71.3 % 
207 
9.7 % 
209 
9.8 
196 
9.2 % 
2129 
100  
a) Adjusted for gender and continuous age 
b) Adjusted for cohabitant, work status and education 
c) Adjusted for physical activity, body mass index (BMI), somatic diseases (Heart attack, Angina Pectoris, Diabetes, Cancer, Apoplexy and other chronic somatic disorder) and 
smoking. 
